Company · Healthtech & Bio

Bioherent

bioherent.com ↗ ·Málaga ·Seed

Bioherent is a deep-tech spin-off of the University of Málaga (founded 2021) developing photonic biosensors for in vitro diagnostics, with its flagship AllerWAVE platform enabling fast, accurate detection of antibiotic allergies and acute drug reactions. The company combines silicon photonics, surface chemistry/nanomaterials and clinical immunology, and also offers a BioXPLORER benchtop analyzer and OEM biosensor modules. It is a Seed-stage company headquartered in Málaga, Spain, backed by Bullnet Capital, CDTI Innvierte and Axon Partners Group.

Founded

2021

Founders

News

Rounds

Investors

SectorsDiagnostics, Photonics, Medical devices, Deep tech Start-up MapHealthtech & Bio › Diagnostics & precision medicine testing

Profile updated 31 Jul 2026

Founders

Ezequiel Pérez-Inestrosa

Co-Founder

—

Iñigo Molina-Fernández

Co-Founder & Head of Photonics/RF Research

Jonas Leuermann

Co-Founder & Head of Innovation

María José Torres Jaén

Co-Founder

—

Global models 5

LumiraDx

United Kingdom · www.lumiradx.com ↗

Point-of-care diagnostic device platform running rapid multi-condition tests, the same device-based near-patient diagnostics model as Bioherent's photonic biosensor platform.

$780MComparable

Cue Health

United States · www.cuehealth.com ↗

Built a portable molecular diagnostics device for rapid point-of-care/at-home testing, matching Bioherent's hardware-based rapid diagnostic approach.

$600MComparable

Visby Medical

United States · www.visbymedical.com ↗

Develops a single-use point-of-care molecular testing device, the same rapid diagnostic-device model Bioherent applies to drug allergy testing.

$500MComparable

Karius

United States · kariusdx.com ↗

Offers a novel diagnostic test to detect hard-to-diagnose conditions from a blood sample, paralleling Bioherent's biomarker-based diagnostic test model.

$315MComparable

Genalyte

United States · www.genalyte.com ↗

Uses a silicon photonic microring biosensor chip (Maverick platform) for multiplexed protein diagnostics from a drop of blood — the closest direct technology match to Bioherent's photonic biosensor approach.

$150MComparable